

Author /year	<i>Holdstock/2016</i>		<i>Meadowcroft/2018</i>		<i>Singh/2021</i>		<i>Akizawa/2020</i>	
Characteristic	Daprodustat	rhEPO	Daprodustat	Control	Daprodusta	ESA	Roxadustat	DA
Number	62	20	171	39	1487	1477	150	151
Age- years±SD	57.8±16.8	64.2±12.8	59.6±13.3	59.7±18.7	58 (48-67)	58 (47-68)	64.6 (11.7)	64.9(10.1)
BMI, kg/m ²	30±8	29±8	27.7±7.5	27.2±5.8	26.8 (23.0-31.2)	26.8(23.2-31.3)	NA	NA
Men (%)	43 (69)	16 (80)	108 (63)	26 (67)	851 (57.2)	847 (57.3)	101 (67.3)	107 (70.9)
Double-blind	Yes		Yes		No		Yes	
Ferritin, µg/l	734.96±386.8	441.76±252.4	585.1±429.7	459.0±261.0	589 (344–976)	604 (341–948)	102.31(83.45)	96.28 (75.14)
Transferrin, g/dl	1.96±0.4	1.76±0.5	NA	NA	NA	NA	1.802(0.327)	1.810(0.297)
TIBC, µmol/l	44.66±8.5	41.16±8.9	41.6±6.6	41.2±7.2	39 (34–43)	39 (34–43)	43.4 (7.0)	43.5 (6.2)
Serum iron, µmol/l	12.56±5.5	12.86±3.4	13.4±6.1	13.4±4.9	13 (10–16)	13 (10–16)	12.1 (5.1)	12.6 (4.5)
Hepcidin, µg/l	483.1(93.5,1241.8)	286.3(61.5,893.7)	388.2(352.9,427.1)	334.4(274.7,407.1)	172.7(109.3-256)	179.6(108.4–251.9)	NA	NA
TSAT, %	32.66±12.0	28.46±12.3	29.6(27.9, 31.5)	30.7(27.0, 35.0)	33 (26–41)	32 (26–42)	28.28 (11.70)	29.04 (10.18)
Hgb, g/dl	NA	NA	10.4 (0.66)	10.6 (0.94)	10.35±0.97	10.39±0.98	11.02 (0.56)	11.01 (0.60)
Hypertension, n (%)	19 (95)	20 (100)	160 (90)	37 (95)	1366 (91.9)	1373 (93.0)	NA	NA
Diabetes, n (%)	8 (40)	11 (55)	62 (35)	18 (46)	615 (41.4)	617 (41.8)	54 (36.0)	54 (35.8)
Myocardial infarction n(%)	NA	NA	NA	NA	122 (8.2)	135 (9.1)	NA	NA
Hemofiltration/Hemodiafiltration, n(%)	0(0)	0(0)	57(32)	7(18)	0(0)	0(0)	0(0)	0(0)
Hemodialysis, n(%)	62(100)	20(100)	120(68)	33(85)	1316 (88.5)	1308 (88.6)	150(100)	151(100)
Peritoneal dialysis, n(%)	0(0)	0(0)	0(0)	0(0)	171 (11.5)	169 (11.4)	0(0)	0(0)

Author /year	<i>Barratt/2021</i>		<i>Chen/2017</i>		<i>Chen/2019</i>		<i>Chen/2021</i>
Characteristic	Roxadustat	ESA	Roxadustat	rhEPO	Roxadustat	Epoetin alfa	All populations
Number	2354	2360	74	22	204	100	55
Age- years±SD	55.5±14.9	56.3±14.6	50.8±12.6	53.8±10.0	47.6±11.7	51.0±11.8	47.6 6 10.3
BMI, kg/m ²	NA	NA	NA	NA	NA	NA	25.0 6 3.5
Men (%)	1365 (58)	1379 (58.4)	45 (61)	13 (59.1)	126 (61.8)	58 (58)	26 (47.3)
Double-blind	No		No		No		No
Ferritin, µg/l	NA	NA	450.5(369.8)	458(361)	498.5±487.4	420.1±406.8	393.2±254.8
Transferrin, g/dl	NA	NA	189.3(45.5)	187(35)	1.89±0.46	1.91±0.39	1.7±0.5
TIBC,µmol/l	NA	NA	217.3(50.2)	214(38)	47.4±11.4	48.3±9.0	NA
Serum iron, µmol/l	NA	NA	71.5(32.9)	79(31.9)	NA	NA	12.2±7.0
Hepcidin, µg/l	NA	NA	176.3(120.6)	209(127.1)	NA	NA	NA
TSAT, %	NA	NA	31.56(16.91)	34.1(14.6)	33.8±16.6	30.0±13.8	NA
Hgb, g/dl	10.32 (0.99)	10.37 (0.99)	10.6(1.0)	10.8(0.7)	10.4±0.7	10.5±0.7	7.8±1.3
Hypertension, n (%)	684 (29.1)	707 (30.0)	NA	NA	NA	NA	18 (32.7)
Diabetes, n (%)	799 (33.9)	813 (34.4)	NA	NA	30 (14.7)	17 (17.0)	NA
Myocardial infarction n(%)	NA	NA	NA	NA	NA	NA	NA
Hemofiltration/Hemodiafiltration, n(%)	NA	NA	0(0)	0(0)	0(0)	0(0)	NA
Hemodialysis, n(%)	2137 (90.8)	2156 (91.4)	74(100)	22(100)	182 (89.2)	89 (89.0)	NA
Peritoneal dialysis, n(%)	0(0)	0(0)	0(0)	0(0)	22 (10.8)	11 (11.0)	NA

Author /year	<i>Csiký/2021</i>		<i>Hou/2021</i>		<i>Provenzano/2016</i>		<i>Provenzano/2021</i>	
Characteristic	Roxadustat	ESA	Roxadustat	ESAs	Roxadustat	Epoetin alfa	Roxadustat	Epoetin alfa
Number	414	420	86	43	67	23	522	521
Age- years±SD	61.0±13.8	61.8±13.4	48±12	48.3±13	56.9±12.1	57.0±11.6	53.8±14.7	54.3±14.6
BMI, kg/m ²	26.87 (4.86)	26.95 (5.59)	23.7±3.5	24.1±3.2	NA	NA	NA	NA
Men (%)	245 (59.2)	235 (56)	47 (55)	25 (58)	45 (67)	14 (61)	309 (59.2)	307 (58.9)
Double-blind	No		Yes		No		No	
Ferritin, µg/l	NA	NA	268.8±297.2	257.4±190.8	827.7±474.3	1,065.8±657.2	441.4 (337.0)	437.4 (311.4)
Transferrin, g/dl	NA	NA	2.0±0.5	1.9±0.6	NA	NA	NA	NA
TIBC, µmol/l	NA	NA	42.5±11.7	41.3±14.9	199.7±34.0	202.1±26.7	241.04 (43.00)	238.06 (37.04)
Serum iron, µmol/l	NA	NA	12.6±5.0	11.4±5.0	66.4±20.6	63.3±32.0	64.41 (24.24)	65.52 (24.15)
Hepcidin, µg/l	NA	NA	NA	NA	327.1±178.8	298.7±123.1	173.21 (120.21)	169.91 (127.98)
TSAT, %	NA	NA	31.3±14.2	29.6±13.2	29.2±10.0	28.1±14.4	27.0 (9.3)	27.6 (8.9)
Hgb, g/dl	10.75 (0.62)	10.78 (0.62)	9.0±1.4	9.0±1.2	11.2±0.7	11.2±1.0	8.4 (1.0)	8.5 (1.0)
Hypertension, n (%)	124 (30.0)	120 (28.6)	29 (34)	14 (33)	66(100)	22(100)	505 (96.7)	504 (96.7)
Diabetes, n (%)	74 (17.9)	95 (22.6)	12 (14)	8 (19)	39(59)	14(64)	205 (39.3)	204 (39.2)
Myocardial infarction n(%)	NA	NA	NA	NA	NA	NA	33 (6.3)	33 (6.3)
Hemofiltration/Hemodiafiltration, n(%)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Hemodialysis, n(%)	379 (91.5)	405 (96.4)	0(0)	0(0)	67(100)	23(100)	469 (89.8)	462 (88.7)
Peritoneal dialysis, n(%)	35 (8.5)	15 (3.6)	86(100)	43(100)	0(0)	0(0)	53 (10.2)	58 (11.1)

Author /year	Akizawa/2019		Akizawa/2021		Eckardt/2021		Nangaku/2020		Nangaku/2021	
Characteristic	Enarodusta	Placebo	Enarodusta	DA	Vadadustat	DA	Vadadusta	Placebo	Vadadustat	DA
Number	60	22	86	86	1777	1777	44	14	162	161
Age- years±SD	61.9 ± 11.2	60.7 ± 13.0	63.2 ± 10.8	64.8 ± 10.3	57.9±13.9	58.4±13.8	63.3±9.2	65.7±11.6	66.0±11.3	64.9±11.7
BMI, kg/m2	NA	NA	NA	NA	NA	NA	24±4.5	22.4±4	22.4±3.4	22.4±4.5
Men (%)	45 (75)	15 (68)	61 (70.9)	61 (70.9)	990 (55.7)	1004 (56.5)	32 (73)	8 (57)	104 (64.2)	109 (67.7)
Double-blind	Yes		Yes		No		Yes		Yes	
Ferritin, µg/l	98.6(36.7,169)	81.0(37.9, 115.0)	90.90(12.3,794)	90.30(12.4, 609)	NA	NA	217.8(113)	294.6(215)	144.5±139.6	140.0±95.3
Transferrin, g/dl	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
TIBC, µmol/l	231.5(207,250)	248.0(216.0,273)	233.0 (179, 241)	243.0 (172, 261)	NA	NA	233.3(35.6)	207.6(34.2)	NA	NA
Serum iron, µmol/l	63.5 (52.0, 77)	62.5 (52.0, 76)	65.5(33, 144)	64.0 (9, 167)	NA	NA	98.5 (31.5)	100.9 (25.5)	NA	NA
Hepcidin, µg/l	64.9(37.0,156)	67.1 (24.6, 127)	70.5(0.34,309)	51.5(1.67, 218)	NA	NA	140.1(61.3)	184.6 (94.3)	NA	NA
TSAT, %	27.5(23.3, 35.4)	23.7 (22.1, 30)	27.0(11, 69)	27.0 (4, 64)	NA	NA	43.63(16.6)	49.78 (15.4)	28.6±10.6	26.9±9.4
Hgb, g/dl	NA	NA	10.79 (0.65)	10.87 (0.70)	10.6±0.9	10.2±0.8	9.0 (0.6)	9.0 (0.6)	10.73±0.7	10.73±0.7
Hypertension, n (%)	NA	NA	NA	NA	NA	NA	13 (29.5)	6 (42.9)	152 (93.8)	147 (91.3)
Diabetes, n (%)	17(28.33)	2 (9.1)	31 (36.0)	36 (41.9)	971 (54.6)	998 (56.2)	19 (43)	5 (36)	35 (21.6)	49 (30.4)
Myocardial infarction n(%)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Hemofiltration/Hemodiafiltration, n(%)	NA	NA	0(0)	0(0)	NA	NA	NA	NA	NA	NA
Hemodialysis, n(%)	60(100)	22(100)	86(100)	86(100)	1652 (93.0)	1633 (91.9)	NA	NA	NA	NA
Peritoneal dialysis, n(%)	NA	NA	0(0)	0(0)	137 (7.7)	143 (8.0)	NA	NA	NA	NA

DA: darbepoetine; BMI: body mass index; TIBC: total iron-binding capacity; TSAT: transferrin saturation; Hgb: hemoglobin